1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Hepatitis C: Drug Development Pipeline Study, H2 2018

Hepatitis C: Drug Development Pipeline Study, H2 2018

  • June 2018
  • 150 pages
  • ID: 5446604
  • Format: PDF
  • By VPAResearch


Table of Contents

With an estimated market value of over $30 billion by 2020, the Hepatitis C industry is considered as the rapidly growing healthcare markets. Hepatitis C affects around 200 million people worldwide and is associated with highest treatment failure rates. Currently, no vaccine is available against HCV. Due to the mutations in Hepatitis C virus, development of a prophylactic vaccine is highly challenging.

The condition is classified into 6 genotypes, of which GT-1 genotype is the most prevalent. The condition is a contagious liver disease which can be either acute or chronic. It can rapidly progress into serious liver problems including cirrhosis or liver cancer.

Hepatitis C pipeline comprises of 85 active drugs under active development as of June 2018. Of these, 16 drugs are in Phase 1 and 19 drugs in phase 2. Only 4 drugs progressed to Phase 3. Further, 27 drugs are in Pre-clinical stage, 18 drugs in research/discovery stages.

60 companies are developing the pipeline for Hepatitis C. Of this, GinkgoPharma Co. Ltd, Biocad CJSC, Cocrystal Pharma Inc, ARA Healthcare Pvt Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Beijing Kawin Technology Share-Holding Co., Ltd. and Achillion Pharmaceuticals, Inc. have more compounds in pipeline. On the other hand, Presidio Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Ascletis, Inc. and Beijing Kawin Technology Share-Holding Co., Ltd. have most advanced pipeline products.

Mechanism of Action of most of the therapeutic candidates is HCV NS5A Inhibitors, Immunostimulants and Immunomodulators.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Hepatitis C (HCV) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Hepatitis C (HCV) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Hepatitis C (HCV) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020

Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020SummaryFibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC pipeline Target constitutes close to 23 molecules. Out of which ...

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2019

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2019SummaryHepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral ...

Ischemia Reperfusion Injury - Pipeline Review, H2 2019

Ischemia Reperfusion Injury - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Ischemia Reperfusion Injury - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2019, provides an overview of the Ischemia ...

Download Unlimited Documents from Trusted Public Sources

HIV Antiviral Market and HIV AIDS Statistics

  • February 2020
    13 pages
  • HIV Antiviral  

    HIV AIDS  

  • Uganda  



View report >

Vaccine Market in the UK

  • February 2020
    11 pages
  • Vaccine  

  • United Kingdom  


View report >

Vaccine Market and Infectious Disease Statistics in the US

  • February 2020
    28 pages
  • Vaccine  

    Infectious Dise...  


  • United States  

    North America  

View report >


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on